Cerus Corp
NASDAQ:CERS

Watchlist Manager
Cerus Corp Logo
Cerus Corp
NASDAQ:CERS
Watchlist
Price: 2.18 USD 1.4% Market Closed
Market Cap: 418.8m USD

Cerus Corp
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cerus Corp
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Cerus Corp
NASDAQ:CERS
Operating Income
-$9.5m
CAGR 3-Years
33%
CAGR 5-Years
31%
CAGR 10-Years
17%
Haemonetics Corp
NYSE:HAE
Operating Income
$253.8m
CAGR 3-Years
22%
CAGR 5-Years
17%
CAGR 10-Years
17%
ICU Medical Inc
NASDAQ:ICUI
Operating Income
$130.7m
CAGR 3-Years
36%
CAGR 5-Years
1%
CAGR 10-Years
6%
Align Technology Inc
NASDAQ:ALGN
Operating Income
$646.2m
CAGR 3-Years
-5%
CAGR 5-Years
15%
CAGR 10-Years
14%
Lantheus Holdings Inc
NASDAQ:LNTH
Operating Income
$345.4m
CAGR 3-Years
26%
CAGR 5-Years
67%
CAGR 10-Years
24%
Merit Medical Systems Inc
NASDAQ:MMSI
Operating Income
$167.1m
CAGR 3-Years
23%
CAGR 5-Years
29%
CAGR 10-Years
14%
No Stocks Found

Cerus Corp
Glance View

Market Cap
418.6m USD
Industry
Health Care

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 294 full-time employees. The company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.

CERS Intrinsic Value
1.53 USD
Overvaluation 30%
Intrinsic Value
Price

See Also

What is Cerus Corp's Operating Income?
Operating Income
-9.5m USD

Based on the financial report for Sep 30, 2025, Cerus Corp's Operating Income amounts to -9.5m USD.

What is Cerus Corp's Operating Income growth rate?
Operating Income CAGR 10Y
17%

Over the last year, the Operating Income growth was 20%. The average annual Operating Income growth rates for Cerus Corp have been 33% over the past three years , 31% over the past five years , and 17% over the past ten years .

Back to Top